Search Results | Clinical Cancer Research | American Association for Cancer Research

1-17 of 17

Sort by

Sort Order Select

Journal Articles

First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies

Kyriakos P. Papadopoulos, Melissa L. Johnson, Albert C. Lockhart, Kathleen Moore, Gerald S. Falchook, Silvia C. Formenti, Aung Naing, Richard D. Carvajal, Lee S. Rosen, Glen J. Weiss, Rom S. Leidner, Jingjin Li, Anne Paccaly, Minjie Feng, Elizabeth Stankevich, Israel Lowy, Matthew G. Fury, Marka R. Crittenden

Clin Cancer Res (2020) 26 (5): 1025–1033.

DOI: https://doi.org/10.1158/1078-0432.CCR-19-2609

Published: 02 March 2020

View article

Includes: Supplementary data

Journal Articles

A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer

Lee S. Rosen, Jonathan W. Goldman, Alain P. Algazi, P. Kellie Turner, Brian Moser, Tianle Hu, Xuejing Aimee Wang, Jay Tuttle, Volker Wacheck, James E. Wooldridge, Michaela Banck

Clin Cancer Res (2017) 23 (8): 1910–1919.

DOI: https://doi.org/10.1158/1078-0432.CCR-16-1418

Published: 13 April 2017

View article

Includes: Supplementary data

Journal Articles

Phase I Dose-Escalation Trial of the Oral Investigational Hedgehog Signaling Pathway Inhibitor TAK-441 in Patients with Advanced Solid Tumors

Jonathan Goldman, S. Gail Eckhardt, Mitesh J. Borad, Kelly K. Curtis, Manuel Hidalgo, Emiliano Calvo, David P. Ryan, Lori J. Wirth, Asit Parikh, James Partyka, Helene Faessel, Esha Gangolli, Sally Stewart, Lee S. Rosen, Daniel W. Bowles

Clin Cancer Res (2015) 21 (5): 1002–1009.

DOI: https://doi.org/10.1158/1078-0432.CCR-14-1234

Published: 01 March 2015

View article

Includes: Supplementary data

Journal Articles

An Open-Label Phase Ib Dose-Escalation Study of TRC105 (Anti-Endoglin Antibody) with Bevacizumab in Patients with Advanced Cancer

Michael S. Gordon, Francisco Robert, Daniela Matei, David S. Mendelson, Jonathan W. Goldman, E. Gabriela Chiorean, Robert M. Strother, Ben K. Seon, William D. Figg, Cody J. Peer, Delia Alvarez, Bonne J. Adams, Charles P. Theuer, Lee S. Rosen

Clin Cancer Res (2014) 20 (23): 5918–5926.

DOI: https://doi.org/10.1158/1078-0432.CCR-14-1143

Published: 30 November 2014

View article

Journal Articles

A Phase I Study of the HSP90 Inhibitor Retaspimycin Hydrochloride (IPI-504) in Patients with Gastrointestinal Stromal Tumors or Soft-Tissue Sarcomas

Andrew J. Wagner, Rashmi Chugh, Lee S. Rosen, Jeffrey A. Morgan, Suzanne George, Michael Gordon, Joi Dunbar, Emmanuel Normant, David Grayzel, George D. Demetri

Clin Cancer Res (2013) 19 (21): 6020–6029.

DOI: https://doi.org/10.1158/1078-0432.CCR-13-0953

Published: 31 October 2013

View article

Includes: Supplementary data

Journal Articles

Phase I Study of BIIB028, a Selective Heat Shock Protein 90 Inhibitor, in Patients with Refractory Metastatic or Locally Advanced Solid Tumors

David Hong, Rabih Said, Gerald Falchook, Aung Naing, Stacy Moulder, Apostolia-Maria Tsimberidou, Gerald Galluppi, Naveen Dakappagari, Chris Storgard, Razelle Kurzrock, Lee S. Rosen

Clin Cancer Res (2013) 19 (17): 4824–4831.

DOI: https://doi.org/10.1158/1078-0432.CCR-13-0477

Published: 02 September 2013

View article

Includes: Supplementary data

Journal Articles

A Multicenter, Phase I, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Etirinotecan Pegol in Patients with Refractory Solid Tumors

Gayle S. Jameson, John T. Hamm, Glen J. Weiss, Carlos Alemany, Stephen Anthony, Michele Basche, Ramesh K. Ramanathan, Mitesh J. Borad, Raoul Tibes, Allen Cohn, Ioana Hinshaw, Robert Jotte, Lee S. Rosen, Ute Hoch, Michael A. Eldon, Robert Medve, Katrina Schroeder, Erica White, Daniel D. Von Hoff

Clin Cancer Res (2013) 19 (1): 268–278.

DOI: https://doi.org/10.1158/1078-0432.CCR-12-1201

Published: 02 January 2013

View article

Journal Articles

A Phase I First-in-Human Study of TRC105 (Anti-Endoglin Antibody) in Patients with Advanced Cancer

Lee S. Rosen, Herbert I. Hurwitz, Michael K. Wong, Jonathan Goldman, David S. Mendelson, William D. Figg, Shawn Spencer, Bonne J. Adams, Delia Alvarez, Ben K. Seon, Charles P. Theuer, Bryan R. Leigh, Michael S. Gordon

Clin Cancer Res (2012) 18 (17): 4820–4829.

DOI: https://doi.org/10.1158/1078-0432.CCR-12-0098

Published: 30 August 2012

View article

Journal Articles

Safety and Pharmacokinetics of Ganitumab (AMG 479) Combined with Sorafenib, Panitumumab, Erlotinib, or Gemcitabine in Patients with Advanced Solid Tumors

Lee S. Rosen, Igor Puzanov, Gregory Friberg, Emily Chan, Yuying C. Hwang, Hongjie Deng, Jill Gilbert, Devalingam Mahalingam, Ian McCaffery, Shaunita A. Michael, Alain C. Mita, Monica M. Mita, Marilyn Mulay, Poornima Shubhakar, Min Zhu, John Sarantopoulos

Clin Cancer Res (2012) 18 (12): 3414–3427.

DOI: https://doi.org/10.1158/1078-0432.CCR-11-3369

Published: 14 June 2012

View article

Includes: Supplementary data

Journal Articles

A Phase I Dose-Escalation Study of Tivantinib (ARQ 197) in Adult Patients with Metastatic Solid Tumors

Lee S. Rosen, Neil Senzer, Tarek Mekhail, Ram Ganapathi, Feng Chai, Ronald E. Savage, Carol Waghorne, Giovanni Abbadessa, Brian Schwartz, Robert Dreicer

Clin Cancer Res (2011) 17 (24): 7754–7764.

DOI: https://doi.org/10.1158/1078-0432.CCR-11-1002

Published: 18 December 2011

View article

Journal Articles

Phase I Safety and Pharmacokinetic Study of Bavituximab, a Chimeric Phosphatidylserine-Targeting Monoclonal Antibody, in Patients with Advanced Solid Tumors

David E. Gerber, Alison T. Stopeck, Lucas Wong, Lee S. Rosen, Philip E. Thorpe, Joseph S. Shan, Nuhad K. Ibrahim

Clin Cancer Res (2011) 17 (21): 6888–6896.

DOI: https://doi.org/10.1158/1078-0432.CCR-11-1074

Published: 31 October 2011

View article

Journal Articles

Phase 1 Experience with an Anti-Glycotope Monoclonal Antibody, RAV12, in Recurrent Adenocarcinoma

Howard A. Burris, III, Lee S. Rosen, Caio M. Rocha-Lima, John Marshall, Suzanne Jones, Roger B. Cohen, Lori A. Kunkel, Deryk Loo, Jan Baughman, Stanford J. Stewart, Nancy Lewis

Clin Cancer Res (2010) 16 (5): 1673–1681.

DOI: https://doi.org/10.1158/1078-0432.CCR-09-2263

Published: 28 February 2010

View article

Journal Articles

Phase I Study of Eribulin Mesylate Administered Once Every 21 Days in Patients with Advanced Solid Tumors

Antoinette R. Tan, Eric H. Rubin, Diana C. Walton, Dale E. Shuster, Y. Nancy Wong, Fang Fang, Simon Ashworth, Lee S. Rosen

Clin Cancer Res (2009) 15 (12): 4213–4219.

DOI: https://doi.org/10.1158/1078-0432.CCR-09-0360

Published: 15 June 2009

View article

Includes: Supplementary data

Journal Articles

New Approaches to Assessing and Treating Early-Stage Colon and Rectal Cancer: Summary Statement from 2007 Santa Monica Conference

Lee S. Rosen, Anton J. Bilchik, Robert W. Beart, Jr., Al B. Benson, III, Kenneth J. Chang, Carolyn C. Compton, Axel Grothey, Daniel G. Haller, Clifford Y. Ko, Patrick M. Lynch, Heidi Nelson, Michael J. Stamos, Roderick R. Turner, Christopher G. Willett

Clin Cancer Res (2007) 13 (22): 6853s–6856s.

DOI: https://doi.org/10.1158/1078-0432.CCR-07-1629

Published: 15 November 2007

View article

Journal Articles

Phase 1 Study of TLK286 (Telcyta) Administered Weekly in Advanced Malignancies

Lee S. Rosen, Bernadette Laxa, Leny Boulos, Laura Wiggins, James G. Keck, Anneliese J. Jameson, Richard Parra, Kiran Patel, Gail L. Brown

Clin Cancer Res (2004) 10 (11): 3689–3698.

DOI: https://doi.org/10.1158/1078-0432.CCR-03-0687

Published: 01 June 2004

View article

Journal Articles

Phase I Study of TLK286 (Glutathione S -Transferase P1-1 Activated Glutathione Analogue) in Advanced Refractory Solid Malignancies

Lee S. Rosen, Joseph Brown, Bernadette Laxa, Leny Boulos, Laura Reiswig, William D. Henner, Robert T. Lum, Steve R. Schow, Christopher A. Maack, James G. Keck, Julie C. Mascavage, Jacqueline A. Dombroski, Reinaldo F. Gomez, Gail L. Brown

Clin Cancer Res (2003) 9 (5): 1628–1638.

Published: 01 May 2003

View article

Journal Articles

A Phase I Dose-ranging Trial of Monthly Infusions of Zoledronic Acid for the Treatment of Osteolytic Bone Metastases

James R. Berenson, Robert A. Vescio, Lee S. Rosen, Joseph M. VonTeichert, Margie Woo, Regina Swift, Allison Savage, Elise Givant, Mieke Hupkes, Harold Harvey, Allan Lipton

Clin Cancer Res (2001) 7 (3): 478–485.

Published: 01 March 2001

View article

NARROW

First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies

A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer

Phase I Dose-Escalation Trial of the Oral Investigational Hedgehog Signaling Pathway Inhibitor TAK-441 in Patients with Advanced Solid Tumors

An Open-Label Phase Ib Dose-Escalation Study of TRC105 (Anti-Endoglin Antibody) with Bevacizumab in Patients with Advanced Cancer

A Phase I Study of the HSP90 Inhibitor Retaspimycin Hydrochloride (IPI-504) in Patients with Gastrointestinal Stromal Tumors or Soft-Tissue Sarcomas

Phase I Study of BIIB028, a Selective Heat Shock Protein 90 Inhibitor, in Patients with Refractory Metastatic or Locally Advanced Solid Tumors

A Multicenter, Phase I, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Etirinotecan Pegol in Patients with Refractory Solid Tumors

A Phase I First-in-Human Study of TRC105 (Anti-Endoglin Antibody) in Patients with Advanced Cancer

Safety and Pharmacokinetics of Ganitumab (AMG 479) Combined with Sorafenib, Panitumumab, Erlotinib, or Gemcitabine in Patients with Advanced Solid Tumors

A Phase I Dose-Escalation Study of Tivantinib (ARQ 197) in Adult Patients with Metastatic Solid Tumors

Phase I Safety and Pharmacokinetic Study of Bavituximab, a Chimeric Phosphatidylserine-Targeting Monoclonal Antibody, in Patients with Advanced Solid Tumors

Phase 1 Experience with an Anti-Glycotope Monoclonal Antibody, RAV12, in Recurrent Adenocarcinoma

Phase I Study of Eribulin Mesylate Administered Once Every 21 Days in Patients with Advanced Solid Tumors

New Approaches to Assessing and Treating Early-Stage Colon and Rectal Cancer: Summary Statement from 2007 Santa Monica Conference

Phase 1 Study of TLK286 (Telcyta) Administered Weekly in Advanced Malignancies

Phase I Study of TLK286 (Glutathione S -Transferase P1-1 Activated Glutathione Analogue) in Advanced Refractory Solid Malignancies

A Phase I Dose-ranging Trial of Monthly Infusions of Zoledronic Acid for the Treatment of Osteolytic Bone Metastases

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only